Accession Number ADA583509
Title Production of a Novel OX40 Ligand for Clinical Use.
Publication Date Oct 2012
Media Count 98p
Personal Author A. D. Weinberg
Abstract Cancer cells have evolved to evade immune-mediated destruction through several documented mechanisms. Our group has developed a technique to enhance immune function in tumor-bearing hosts by targeting a protein on the surface of white blood cells, termed OX40. This type of immune modulation leads to therapeutic benefit in tumor-bearing mice. We have produced a protein that binds to the human OX40 protein and activates human white blood cells. We have a cell line that produces high quantities of this protein and our goal is to test this protein for safety and efficacy in non-human primates so that we can obtain FDA approval for clinical trials in cancer patients. The long-range goal of this proposal is translate these findings to prostate cancer patients.
Keywords Blood cells
Clinical medicine
Clinical trials

Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Angov (Evelina), Bethesda, MD.
Document Type Technical report
Title Note Annual rept. 30 Sep 2011-29 Sep 2012.
NTIS Issue Number 1401
Contract Number W81XWH-11-1-0345

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader